These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 31548814)

  • 21. Three cachexia phenotypes and the impact of fat-only loss on survival in FOLFIRINOX therapy for pancreatic cancer.
    Kays JK; Shahda S; Stanley M; Bell TM; O'Neill BH; Kohli MD; Couch ME; Koniaris LG; Zimmers TA
    J Cachexia Sarcopenia Muscle; 2018 Aug; 9(4):673-684. PubMed ID: 29978562
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium.
    Janssen QP; van Dam JL; Doppenberg D; Prakash LR; van Eijck CHJ; Jarnagin WR; O' Reilly EM; Paniccia A; Besselink MG; Katz MHG; Tzeng CD; Wei AC; Zureikat AH; Groot Koerkamp B;
    J Natl Cancer Inst; 2022 May; 114(5):695-703. PubMed ID: 35157075
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors.
    Vivaldi C; Caparello C; Musettini G; Pasquini G; Catanese S; Fornaro L; Lencioni M; Falcone A; Vasile E
    Int J Cancer; 2016 Aug; 139(4):938-45. PubMed ID: 27038273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival and Predictive Factors of Chemotherapy With FOLFIRINOX as First-Line Therapy in Metastatic Pancreatic Cancer: A Retrospective Multicentric Analysis.
    Caron B; Reimund JM; Ben Abdelghani M; Sondag D; Noirclerc M; Duclos B; Kurtz JE; Nguimpi-Tambou M
    Pancreas; 2021 Jul; 50(6):803-806. PubMed ID: 34347737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma.
    Meijer LL; Garajová I; Caparello C; Le Large TYS; Frampton AE; Vasile E; Funel N; Kazemier G; Giovannetti E
    Ann Surg; 2020 Jun; 271(6):1137-1147. PubMed ID: 30394883
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma with synchronous liver metastasis after treatment with FOLFIRINOX.
    Ozaki K; Hayashi H; Ikuta Y; Masuda T; Akaboshi S; Ogata K; Matumoto K; Ogawa K; Kamio T; Baba H; Takamori H
    Clin J Gastroenterol; 2019 Dec; 12(6):603-608. PubMed ID: 30993652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
    Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
    Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Borderline or locally advanced pancreatic adenocarcinoma: A single center experience on the FOLFIRINOX induction regimen.
    Garnier J; Ewald J; Marchese U; Gilabert M; Moureau-Zabotto L; Giovannini M; Poizat F; Delpero JR; Turrini O
    Eur J Surg Oncol; 2020 Aug; 46(8):1510-1515. PubMed ID: 32146053
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metastatic Pancreatic Carcinoma and Experience with FOLFIRINOX - a Cross Sectional Analysis From a Developing Country.
    Zahir MN; Jabbar AA
    Asian Pac J Cancer Prev; 2015; 16(14):6001-6. PubMed ID: 26320487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial.
    Dahan L; Williet N; Le Malicot K; Phelip JM; Desrame J; Bouché O; Petorin C; Malka D; Rebischung C; Aparicio T; Lecaille C; Rinaldi Y; Turpin A; Bignon AL; Bachet JB; Seitz JF; Lepage C; François E;
    J Clin Oncol; 2021 Oct; 39(29):3242-3250. PubMed ID: 34288696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1.
    Chen LT; Macarulla T; Blanc JF; Mirakhur B; de Jong FA; Belanger B; Bekaii-Saab T; Siveke JT
    Pancreatology; 2021 Jan; 21(1):192-199. PubMed ID: 33214082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.
    Stein SM; James ES; Deng Y; Cong X; Kortmansky JS; Li J; Staugaard C; Indukala D; Boustani AM; Patel V; Cha CH; Salem RR; Chang B; Hochster HS; Lacy J
    Br J Cancer; 2016 Mar; 114(7):737-43. PubMed ID: 27022826
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG).
    Park HS; Kang B; Chon HJ; Im HS; Lee CK; Kim I; Kang MJ; Hwang JE; Bae WK; Cheon J; Park JO; Hong JY; Kang JH; Kim JH; Lim SH; Kim JW; Kim JW; Yoo C; Choi HJ
    ESMO Open; 2021 Apr; 6(2):100049. PubMed ID: 33578192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
    Choi JG; Nipp RD; Tramontano A; Ali A; Zhan T; Pandharipande P; Dowling EC; Ferrone CR; Hong TS; Schrag D; Fernandez-Del Castillo C; Ryan DP; Kong CY; Hur C
    Oncologist; 2019 Jul; 24(7):945-954. PubMed ID: 30559125
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
    Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
    Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic factors in advanced pancreatic ductal adenocarcinoma patients-receiving second-line treatment: a single institution experience.
    Gutierrez-Sainz L; Viñal D; Villamayor J; Martinez-Perez D; Garcia-Cuesta JA; Ghanem I; Custodio A; Feliu J
    Clin Transl Oncol; 2021 Sep; 23(9):1838-1846. PubMed ID: 33866520
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience.
    Moorcraft SY; Khan K; Peckitt C; Watkins D; Rao S; Cunningham D; Chau I
    Clin Colorectal Cancer; 2014 Dec; 13(4):232-8. PubMed ID: 25442814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.
    Nywening TM; Wang-Gillam A; Sanford DE; Belt BA; Panni RZ; Cusworth BM; Toriola AT; Nieman RK; Worley LA; Yano M; Fowler KJ; Lockhart AC; Suresh R; Tan BR; Lim KH; Fields RC; Strasberg SM; Hawkins WG; DeNardo DG; Goedegebuure SP; Linehan DC
    Lancet Oncol; 2016 May; 17(5):651-62. PubMed ID: 27055731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identifying ideal candidates for nanoliposomal topoisomerase inhibitors in metastatic pancreatic adenocarcinoma.
    Yu K
    Clin Adv Hematol Oncol; 2018 Sep; 16 Suppl 17(9):9-10. PubMed ID: 30807562
    [No Abstract]   [Full Text] [Related]  

  • 40. FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial.
    Bachet JB; Lucidarme O; Levache CB; Barbier E; Raoul JL; Lecomte T; Desauw C; Brocard F; Pernot S; Breysacher G; Lagasse JP; Di Fiore F; Etienne PL; Dupuis OJM; Aleba A; Lepage C; Taieb J;
    Eur J Cancer; 2018 Nov; 104():108-116. PubMed ID: 30343254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.